Amgen

YTD

ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.

CEO

Robert A. Bradway

CEORobert A. Bradway

Employees

31,500

Employees31,500

Headquarters

Thousand Oaks, California

HeadquartersThousand Oaks, California

Founded

1980

Founded1980

Employees

31,500

Employees31,500

AMGN Key Statistics

Market cap

217.93B

Market cap217.93B

Price-Earnings ratio

25.30

Price-Earnings ratio25.30

Dividend yield

2.44%

Dividend yield2.44%

Average volume

3.00M

Average volume3.00M

High today

$412.00

High today$412.00

Low today

$401.96

Low today$401.96

Open price

$410.16

Open price$410.16

Volume

3.50M

Volume3.50M

52 Week high

$447.03

52 Week high$447.03

52 Week low

$288.00

52 Week low$288.00

Stock Snapshot

As of today, Amgen(AMGN) shares are valued at $404.00. The company's market cap stands at 217.93B, with a P/E ratio of 25.30 and a dividend yield of 2.44%.

During the trading session on 2026-10-03, Amgen(AMGN) shares reached a daily high of $412.00 and a low of $401.96. At a current price of $404.00, the stock is +0.5% higher than the low and still -1.9% under the high.

Trading volume for Amgen(AMGN) stock has reached 3.5M, versus its average volume of 3M.

The stock's 52-week range extends from a low of $288.00 to a high of $447.03.

AMGN News

Investing.com 6h

David J. Taylor Purchases Amgen and Home Depot Stocks, Sells Marathon Petroleum - Investing.com

...

TipRanks 12h

Amgen’s Evolocumab Study Signals Quiet Efficiency Gains for Cholesterol Franchise

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Amgen’s AMGN Evolocumab Study Highlights Subtle Edge in Cholesterol Drug Delivery The Am...

TipRanks 2d

Amgen’s Pediatric Psoriasis Study in Japan Wraps Up, Setting the Stage for Otezla Growth

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Amgen Inc. (AMGN) has completed a Phase 3 study called “A Phase 3, Multicenter, Open-labe...

Analyst ratings

51%

of 37 ratings

Buy

32.4%

Hold

51.4%

Sell

16.2%

More AMGN News

Simply Wall St 3d

Is Amgen Undervalued Following Its Phase 3 Sjögren's Disease Trial Update?

Amgen (AMGN) is back in focus after reporting positive topline Phase 3 data from its OASIZ 301 trial of dazodalibep in Sjögren's disease, which has sharpened at...

TipRanks 4d

Amgen price target raised to $500 from $450 at Scotiabank

Scotiabank analyst Louise Chen raised the firm’s price target on Amgen (AMGN) to $500 from $450 and keeps an Outperform rating on the shares. The firm notes Amg...

24/7 Wall St. 4d

Why Amgen's 6% Dividend Raise Masks a Tougher Road Ahead

Investing Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead Amgen just handed income investors another dividend raise, but a mountain of acquisition debt...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.